Iodine-124 stands out among positron-emitting radionuclides for its 4.2-day half-life, enabling longitudinal PET imaging of large biomolecules such as monoclonal antibodies and engineered fragments over extended time windows. Protheragen translates this unique isotopic property into dependable radiolabeling solutions, helping sponsors advance their immuno-PET and theranostic pipelines from bench to bedside.
Iodine-124 (124I) is a cyclotron-produced positron emitter with a physical half-life of approximately 4.2 days, making it one of the longest-lived PET radionuclides currently available for molecular imaging. Unlike fluorine-18, which is constrained by a 110-minute half-life, 124I accommodates the slow pharmacokinetics of high-molecular-weight biologics, allowing image acquisition at 24, 48, or even 72 hours post-injection when tumor-to-background contrast is maximized. Its decay scheme involves positron emission with a maximum energy of 2.14 MeV, accompanied by prominent gamma emissions at 603 keV, which demands careful protocol optimization but also opens avenues for quantitative dosimetry and multimodal imaging strategies.
Fig 1. SUVmax comparison of 124I-trastuzumab and 18F-FDG in gastric cancer patients. (Guo, Xiaoyi, et al., 2020)
The radiochemistry of 124I is well established, leveraging both nucleophilic and electrophilic substitution pathways. For direct labeling, electrophilic aromatic substitution targets tyrosine or histidine residues on proteins and peptides using oxidizing agents such as Iodogen or Chloramine-T. Alternatively, indirect methods employ prosthetic groups—such as N-succinimidyl 3-(tri-n-butylstannyl)benzoate (STB) or Bolton-Hunter reagents—to attach 124I to lysine residues, thereby preserving the native binding affinity of the carrier molecule. These versatile chemistries have enabled the successful radiolabeling of antibodies, antibody fragments, peptides, nanoparticles, and small-molecule tyrosine kinase inhibitors, positioning 124I as a cornerstone isotope in preclinical and translational nuclear medicine research.
At Protheragen, our radiochemistry team brings together deep expertise in isotope handling, bioconjugation chemistry, and quality-controlled formulation to deliver 124I radiolabeling services that meet the exacting standards of preclinical and early-phase clinical research. Whether your program requires direct radioiodination of a tyrosine-rich antibody, site-specific labeling via prosthetic group conjugation, or custom synthesis of a 124I-labeled small molecule for PET imaging, we design each campaign around your molecule's unique structural and biological properties. From initial feasibility studies through GMP-ready process development, Protheragen provides end-to-end support that accelerates your radiopharmaceutical pipeline.
We perform tyrosine- and histidine-directed 124I incorporation using mild oxidizing agents such as Iodogen-coated vials or IODO-beads, preserving the immunoreactivity and biological function of antibodies, peptides, and proteins. Reaction conditions are optimized for pH, temperature, and stoichiometry to maximize radiochemical yield while minimizing oxidative damage.
For molecules lacking suitable aromatic residues or where direct iodination would compromise binding affinity, we employ prosthetic group strategies—including Bolton-Hunter reagents, STB derivatives, and click-chemistry linkers—to achieve site-specific 124I conjugation with retained pharmacological activity.
Our chemists utilize copper-assisted nucleophilic exchange reactions for regioselective 124I incorporation into aryl halide precursors, diaryliodonium salts, and arylboronic acid derivatives, delivering high molar activity radiotracers suitable for receptor occupancy studies and low-dose PET imaging.
We specialize in radiolabeling intact monoclonal antibodies, minibodies, diabodies, scFv dimers, and Fc-fusion proteins, with tailored purification protocols (size-exclusion chromatography, affinity capture, or HPLC) that separate labeled product from free iodide and aggregated species.
From meta-iodobenzylguanidine (MIBG) analogs to radiolabeled kinase inhibitors and RGD peptides, we design custom synthetic routes that accommodate the 4.2-day half-life of 124I, enabling extended reaction times and multi-step purifications without significant isotopic decay losses.
We attach 124I to silica nanoparticles, polymeric micelles, and liposomal formulations through surface tyrosine residues or pre-functionalized prosthetic linkers, supporting multimodal imaging platforms that combine PET with optical or magnetic resonance reporters.
Each I-124 radiolabeling project at Protheragen follows a structured, milestone-driven workflow designed to ensure reproducibility, regulatory readiness, and seamless integration with your downstream preclinical or clinical program. Our process balances scientific rigor with operational flexibility, allowing us to adapt timelines and methodologies to the specific physicochemical properties of your candidate molecule.
1. Project Consultation & Feasibility Assessment: We begin with a detailed review of your molecule's sequence, structure, and intended application to select the optimal radiolabeling strategy—direct, indirect, or nucleophilic—and establish preliminary quality targets for radiochemical yield, purity, and specific activity.
2. Precursor Synthesis & Characterization: If indirect labeling is chosen, our synthetic team prepares stannylated, boronic acid, or azide-bearing precursors, confirming identity and purity by NMR and mass spectrometry before introducing radioactivity.
3. Radiolabeling Reaction Optimization: Using non-radioactive iodine-127 or trace-level 124I, we screen oxidizing agents, buffer systems, pH ranges, and reaction times to identify conditions that maximize incorporation efficiency while preserving biological function.
4. No-Carrier-Added 124I Labeling & Purification: The optimized protocol is transferred to a shielded hot cell where no-carrier-added [124I]NaI is introduced. Labeled products are purified by size-exclusion chromatography, C18 solid-phase extraction, or preparative HPLC to achieve radiochemical purity typically exceeding 95%.
5. Analytical Release Testing: Each purified batch is characterized by radio-TLC, analytical radio-HPLC, pH measurement, endotoxin screening, and sterility testing where required, with full documentation provided for your regulatory submissions.
6. Formulation & Stability Evaluation: We formulate the final product in PBS, saline, or custom buffer systems and conduct real-time and accelerated stability studies to establish shelf-life parameters and recommend storage conditions.
7. Preclinical Imaging Support (Optional): Upon request, we coordinate biodistribution, pharmacokinetic, and microPET/CT imaging studies in rodent or non-human primate models, delivering quantitative uptake data and dosimetry estimates to inform your clinical translation strategy.
Ready to advance your radiopharmaceutical program with precision I-124 radiolabeling? Reach out to our scientific team today to discuss your project requirements, receive a tailored proposal, and explore how Protheragen can accelerate your path from candidate selection to clinical proof-of-concept. We welcome the opportunity to partner with you on your next breakthrough in molecular imaging.
Reference